Table 2.
Patient characteristics by facility size and race/ethnicity
| Characteristics | White (n=202,977) | Black (n=125,877) | Hispanic (n=56,220) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 1–15 Stations | 16–30 Stations | ≥31 Stations | 1–15 Stations | 16–30 Stations | ≥31 Stations | 1–15 Stations | 16–30 Stations | ≥31 Stations | |
| Number of patients, n | 61,101 (30.1%) | 126,039 (62.1%) | 15,837 (7.8%) | 21,068 (16.7%) | 82,809 (65.8%) | 22,000 (17.5%) | 8648 (15.4%) | 39,488 (70.2%) | 8084 (14.4%) |
| Men (%) | 57.1 | 57.7 | 57.8 | 49.7 | 49.8 | 50.7 | 56.6 | 55.8 | 55.1 |
| Age, mean ± SD (yr) | 66.7±14.0 | 66.8±14.2 | 65.6±14.6 | 59.3±14.8 | 58.2±14.9 | 57.9±14.8 | 59.2±15.2 | 59.0±15.2 | 58.2±14.8 |
| BMI, mean ± SD (kg/m2) | 29.0±7.7 | 28.7±7.6 | 28.6±7.7 | 29.4±8.2 | 29.4±8.1 | 29.5±8.2 | 28.4±7.1 | 28.2±7.0 | 28.3±7.1 |
| eGFR, mean ± SD (ml/min per 1.73 m2) | 11.1±4.9 | 10.9±4.8 | 10.3±4.6 | 10.6±5.0 | 10.2±4.8 | 9.9±4.6 | 10.0±4.6 | 9.8±4.6 | 9.5±4.5 |
| SES | |||||||||
| Employed (%) | 88.9 | 88.4 | 85.7 | 77.5 | 75.1 | 72.1 | 75.2 | 74.8 | 70.4 |
| Private insurance (%) | 57.8 | 58.9 | 57.1 | 37.7 | 37.0 | 34.9 | 32.5 | 30.1 | 27.6 |
| No insurance (%) | 6.7 | 7.9 | 8.9 | 11.2 | 13.3 | 14.8 | 14.3 | 16.3 | 19.1 |
| Race/ethnicity-specific zip code income ($1000) | 43.9±15.3 | 46.5±15.4 | 45.1±14.1 | 30.6±15.2 | 30.6±13.8 | 28.8±11.8 | 35.2±13.5 | 34.0±12.0 | 33.3±10.9 |
| Current smoker (%) | 7.1 | 6.6 | 7.6 | 6.6 | 6.8 | 8.7 | 3.0 | 2.5 | 2.9 |
| Cause of ESRD (%) | |||||||||
| Diabetes | 44.3 | 43.8 | 43.7 | 46.0 | 45.0 | 43.4 | 62.4 | 63.1 | 64.6 |
| Hypertension | 28.3 | 28.3 | 27.1 | 36.9 | 36.9 | 39.2 | 19.1 | 19.7 | 20.2 |
| GN | 6.6 | 7.1 | 7.7 | 5.0 | 5.6 | 5.6 | 6.4 | 5.7 | 5.1 |
| Other | 16.5 | 16.6 | 17.4 | 9.4 | 9.9 | 9.5 | 8.1 | 8.2 | 7.0 |
| Unknown | 4.3 | 4.1 | 4.1 | 2.7 | 2.6 | 2.3 | 4.1 | 3.3 | 3.2 |
| Comorbidity | |||||||||
| Hypertension (%) | 82.3 | 82.6 | 83.8 | 88.0 | 88.7 | 89.7 | 84.1 | 85.5 | 85.7 |
| Diabetes (%) | 52.4 | 51.3 | 52.7 | 54.5 | 53.5 | 54.2 | 64.8 | 65.8 | 66.5 |
| Cardiac failure (%) | 36.4 | 36.2 | 35.9 | 30.6 | 29.6 | 30.2 | 27.7 | 28.0 | 26.2 |
| Atherosclerotic heart disease (%) | 29.1 | 28.5 | 30.3 | 15.5 | 14.1 | 14.0 | 16.8 | 16.8 | 15.5 |
| Cerebrovascular disease (%) | 10.1 | 9.9 | 10.7 | 10.5 | 9.4 | 10.1 | 6.8 | 7.0 | 6.4 |
| Peripheral vascular disease (%) | 17.1 | 17.1 | 17.3 | 10.6 | 9.5 | 9.3 | 11.1 | 11.7 | 9.7 |
| Chronic obstructive pulmonary disease (%) | 12.7 | 11.9 | 12.0 | 5.7 | 5.4 | 5.7 | 4.2 | 3.2 | 2.8 |
| Pre-ESRD care | |||||||||
| Use of ESA before ESRD (%) | 30.0 | 32.7 | 33.8 | 23.8 | 25.1 | 26.4 | 22.9 | 24.1 | 22.5 |
| Receipt of pre-ESRD nephrologist care (%)a | 61.3 | 62.7 | 64.2 | 52.9 | 53.6 | 54.7 | 48.6 | 49.1 | 46.7 |
| AVF for first dialysis (%)a | 15.8 | 16.9 | 17.8 | 12.0 | 12.9 | 13.4 | 12.7 | 12.2 | 11.2 |
BMI, body mass index; eGFR, estimated GFR; ESA, erythropoiesis-stimulating agent; AVF, arteriovenous fistula.
a
For patients who completed the new CMS Medical Evidence form since 2005.